| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/06/2004 | CA2292629C Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione |
| 01/06/2004 | CA2223588C Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 01/06/2004 | CA2145248C Pharmaceutical compositions containing time-released orally taken trimetazidine |
| 01/02/2004 | EP1375670A1 Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions |
| 01/02/2004 | EP1375645A1 Yeast cells as dietary supplements for enhancing the immune system |
| 01/02/2004 | EP1375519A2 Method for affecting cellular function using antibodies |
| 01/02/2004 | EP1374923A2 Porous implants with antibiotic coating, their preparation and use |
| 01/02/2004 | EP1374908A2 Polymer-drug conjugates comprising hydrazide linkers |
| 01/02/2004 | EP1374907A2 Drug transport and delivery system |
| 01/02/2004 | EP1374906A1 A process for the preparation of piroxicam: beta-cyclodextrin inclusion compounds |
| 01/02/2004 | EP1374905A1 Injectable microdispersions for medical applications |
| 01/02/2004 | EP1374904A1 Preparation containing polymethyl-siloxane for nails, cartilage, bone joint, muscle and tendon disorders |
| 01/02/2004 | EP1374903A1 Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases |
| 01/02/2004 | EP1374891A1 Method for accelerating the rate of mucociliary clearance |
| 01/02/2004 | EP1374874A2 Liquid antacid compositions |
| 01/02/2004 | EP1374861A1 External preparations for treating dermatoses |
| 01/02/2004 | EP1374860A1 Polymer coated microparticles for sustained release |
| 01/02/2004 | EP1374855A1 Medicinal solutions |
| 01/02/2004 | EP1374854A1 Delayed release pharmaceutical composition, method of production and use of said composition |
| 01/02/2004 | EP1374853A1 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/02/2004 | EP1374852A1 Cosmetic and/or dermatological Composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/02/2004 | EP1374851A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/02/2004 | EP1374850A1 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/02/2004 | EP1374849A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/02/2004 | EP1373573A2 Conjugate probes and optical detection of analytes |
| 01/02/2004 | EP1373546A1 Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof |
| 01/02/2004 | EP1373501A2 Targeting molecules for adenoviral vectors |
| 01/02/2004 | EP1373384A1 Antibacterial and fungicidal polymer dispersions and polymer solutions |
| 01/02/2004 | EP1373376A2 Hydrogel attached to backing and method for making same |
| 01/02/2004 | EP1373368A1 Compounds for a controlled release of active compounds |
| 01/02/2004 | EP1373366A2 Multi-arm block copolymers as drug delivery vehicles |
| 01/02/2004 | EP1373321A2 Modified antibodies and methods of use |
| 01/02/2004 | EP1373301A2 Reducing the immunogenicity of fusion proteins |
| 01/02/2004 | EP1373287A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof |
| 01/02/2004 | EP1373285A2 Synthesis and use of glycodendrimer reagents |
| 01/02/2004 | EP1372785A2 Compositions having improved bioavailability of eletriptan |
| 01/02/2004 | EP1372777A1 Embolic devices capable of in-situ reinforcement |
| 01/02/2004 | EP1372748A2 Porous beta-tricalcium phosphate granules and methods for producing same |
| 01/02/2004 | EP1372747A1 Polymerized hydrogel adhesive |
| 01/02/2004 | EP1372742A2 Polymeric imagable brachytherapy seed |
| 01/02/2004 | EP1372741A2 Morpholino imaging and therapy |
| 01/02/2004 | EP1372740A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions |
| 01/02/2004 | EP1372739A2 Stabilized therapeutic and imaging agents |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372734A1 Lectin-directed prodrug delivery system |
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372732A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 01/02/2004 | EP1372731A2 Polydimethylsiloxane preparation for nail, cartilage, bone and joint disorders |
| 01/02/2004 | EP1372730A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 01/02/2004 | EP1372729A1 Erodible polymers for injection |
| 01/02/2004 | EP1372728A1 Compositions comprising an o/w emulsion containing conjugated linoleic acid |
| 01/02/2004 | EP1372727A1 Biodegradable carrier and method for preparation thereof |
| 01/02/2004 | EP1372725A1 Compositions and methods for non-insulin glucose uptake |
| 01/02/2004 | EP1372708A2 Vaccine for transcutaneous immunization |
| 01/02/2004 | EP1372707A1 Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid |
| 01/02/2004 | EP1372700A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 01/02/2004 | EP1372694A1 Liposome targeting of matrix metalloproteinase inhibitors |
| 01/02/2004 | EP1372693A2 Peptides for the treatment of wound contracture |
| 01/02/2004 | EP1372672A1 Prophylactic teat treatment |
| 01/02/2004 | EP1372669A1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 01/02/2004 | EP1372667A2 Compositions for delivering bisphosphonates |
| 01/02/2004 | EP1372666A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial / matrix adhesion such as asthma, cystic fibrosis and influenza |
| 01/02/2004 | EP1372662A1 Taste masked liquid pharmaceutical compositions |
| 01/02/2004 | EP1372649A2 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 01/02/2004 | EP1372645A1 Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 01/02/2004 | EP1372637A2 Premixed amiodarone parenteral solution and method for making the same |
| 01/02/2004 | EP1372628A2 Paracetamol solutions which are stable in storage and ready for infusion |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372622A1 Parasiticidal compositions and methods of use |
| 01/02/2004 | EP1372619A2 Highly flexible transdermal therapeutic system having nicotine as active substance |
| 01/02/2004 | EP1372616A2 A stable pharmaceutical composition of pravastatin |
| 01/02/2004 | EP1372615A1 Compounds and compositions for delivering active agents |
| 01/02/2004 | EP1372611A2 Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| 01/02/2004 | EP1372610A2 Powder inhaler formulations |
| 01/02/2004 | EP1372608A1 Medical aerosol formulations |
| 01/02/2004 | EP1372607A1 Adjuvant emulsion and method of using said emulsion |
| 01/02/2004 | EP1372606A2 In-situ gel formation of pectins |
| 01/02/2004 | EP1372605A2 Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| 01/02/2004 | EP1372604A2 Manufacturing dissolvable dosage forms |
| 01/02/2004 | EP1372573A2 Thermally reversible water in oil in water emulsions |
| 01/02/2004 | EP1372528A2 Mucosal boosting following parenteral priming |
| 01/02/2004 | EP1372394A1 Antifungal composition with enhanced bioavailability |
| 01/02/2004 | EP1372392A1 Nicotine-containing oral dosage form |
| 01/02/2004 | EP1204595B1 Polytype mg-ai hydrotalcite |
| 01/02/2004 | EP0719343B1 Adeno-associated viral (aav) liposomes and methods related thereto |
| 01/01/2004 | US20040003418 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer |
| 01/01/2004 | US20040002590 Tumour necrosis factor peptide binding antibodies |
| 01/01/2004 | US20040002589 Tumour necrosis factor peptide binding antibodies |
| 01/01/2004 | US20040002588 Ligands which bind to human tumour necrosis factor alpha (TNF) in a manner that modifies the TNF |
| 01/01/2004 | US20040002522 Antiinflammatory agents; analgesics |
| 01/01/2004 | US20040002482 Androgen pharmaceutical composition and method for treating depression |
| 01/01/2004 | US20040002479 Proteasome inhibitors; bone disorders |
| 01/01/2004 | US20040002477 Therapy for sexual disorders; chealte compound with cyclodextrin |
| 01/01/2004 | US20040002472 Vaccination or immunization using a prime-boost regimen |
| 01/01/2004 | US20040002469 Administering genetic engineered polynucleotide which codes heat shock protein; induce immunology response |
| 01/01/2004 | US20040002466 Releasing interferon from complex of interferon and nucleic acids; antitumor agents, viricide, induction immunology response |
| 01/01/2004 | US20040002461 Amelioration of the development of cataracts and other ophthalmic diseases |
| 01/01/2004 | US20040002456 Methods and devices for preparing protein concentrates |
| 01/01/2004 | US20040002455 Targeted immunogens |
| 01/01/2004 | US20040002451 Antiinflammatory agents; stability, reduced viscosity; immobilization |